|
|
3-异丁基-1-甲基黄嘌呤 |
| CAS No.: |
28822-58-4 |
| 分子式： |
C10H14N4O2 |
| 分子量： |
222.24 |
| 备注： |
中文名称3-异丁基-1-甲基黄嘌呤中文同义词3-异丁基-1-甲基-2,6(1H,3H)-嘌呤二酮;3-异丁基-1-甲基黄嘌呤(IBMX),99%;3-ISOBUTYL-1-METHYLXANTHINE3-异丁基-1-甲基黄嘌呤IBMX;3-异丁基-1-甲基黄嘌呤(IBMX、1-甲基-3-异丁基黄嘌呤、3,7-二氢-3-异丁基-1-甲基-1H-嘌呤-2,6-二酮);3-异丁基-1-甲基-1H-嘌呤-2,6(3H,9H)-二酮;3-异丁基-1-甲基-3,9-二氢-1H-嘌呤-2,6-二酮;IBMX、1-甲基-3-异丁基黄嘌呤;3-异丁基-1-甲基黄嘌呤(IBMX)英文名称3-ISOBUTYL-1-METHYLXANTHINE英文同义词1H-Purine-2,6-dione,3,7-dihydro-1-methyl-3-(2-methylpropyl)-;3,7-dihydro-1-methyl-3-(2-methylpropyl)-1h-purine-6-dione;3-Isobutyl-1-methyl-3,7-dihydro-1H-purine-2,6-dione;3-Isobutyl-1-methylanxthine;3-isobutyl-1-methyl-xanthin;IMX;Isobutylmethylxanthine;MethylisobutylxanthineCAS号28822-58-4分子式C10H14N4O2分子量222.24EINECS号249-259-3相关类别生化试剂;小分子抑制剂;嘌呤;有机砌块;其他生化试剂;杂环砌块;其他化学试剂;科研试剂;标准品;其它;原料;Inhibitors;AllInhibitors;Intermediates&FineChemicals;PharmaceuticalsMol文件28822-58-4.mol结构式3-异丁基-1-甲基黄嘌呤性质熔点200-201°C(lit.)沸点363.42°C(roughestimate)密度1.2042(roughestimate)折射率1.6500(estimate)储存条件-20°C溶解度DMSO：1M，慢慢升温酸度系数(pKa)8.61±0.70(Predicted)形态粉末颜色米白色BRN247859稳定性可在-20°C下的DMSO或乙醇溶液保存长达3个月。InChIKeyAPIXJSLKIYYUKG-UHFFFAOYSA-NCAS数据库28822-58-4(CASDataBaseReference)3-异丁基-1-甲基黄嘌呤用途与合成方法生物活性IBMX(Isobutylmethylxanthine,1-Methyl-3-Isobutylxanthine)是一种非特异性phosphodiesterase(PDE)抑制剂，对PDE3、PDE4、PDE5的IC50值分别为6.5±1.2,26.3±3.9和31.7±5.3μM。它能增强细胞内cAMP水平，是adenosine(A1)receptor拮抗剂。靶点TargetValuePDE3()6.5μMPDE4()26.3μMPDE5()31.7μM体外研究At100μM,KMUP-1(axanthinederivative)andIBMXarethemosteffectiveatinducingtrachealrelaxation;themagnitudeoftherelaxationresponsesinducedbyKMUP-1andIBMXareChemicalbooknotsignificantlydifferent.IBMX(100μM)activatesrenaloutermedullaryK+(ROMK)channels(n=6,P<0.05)andpreventsfurtherchannelactivationbyANGII(n=6,P=NS)orcGMP.Ofnoteisthatpretreatmentofcorticalcollectingduct(CCDs)isolatedfromhigh-K+(HK)-fedratswithIBMX(100μM)for20minleadstoasignificantincreaseintubularcAMPcontentto1.43±0.35pg/mmtubulelength(n=14)comparewiththatmeasuredinvehicle-treatedcontrols(0.61±0.13pg/mmtubulelength,n=12,P<0.05).体内研究IBMX,anon-selectivePDEinhibitorsignificantlydecreasestheliverglycogenstorage(mg/g,IBMX22±1.5P<0.001).Incomparisonwiththecontrolgroup,IBMXandmc5significantlyincreaseplasmaglucose(bloodglucose,mg/dl,control=141±3,IBMX=210±17P<0.001andmc5=191±13P<0.01)whileothertestcompounds(mc1,mc6,MCPIPandWin47203)donotproducesignificanteffect(control=141±3,mc1160±7,mc6175±9,MCPIP179±8andWin47203116±2P>0.05)alsomc2doesnotchangeplasmaglucose(control=141±3andmc2=145±5).IBMXhasthehighestefficacyonincreasingplasmaglucose.TreatmentswithIBMXandApocyninsignificantlydecreasecold-inducedelevationofrightventricular(RV)systolicpressure(23.5±1.8and24.2±0.6mmHg,respectively)althoughtheydonotdecreaseRVpressuretothewarmcontrollevels.IBMXorApocyninsignificantlyreducesmediallayerthickness(19.0±0.9,and16.9±0.8μm,respectively)andincreaseslumendiameter(62.7±4.2,and59.5±4.3μm,respectively)ofsmallPAsincold-exposedrats.用途环核苷酸磷酸二酯酶蛋白抑制剂。用途cAMP和cGMP磷酸二脂酶的非专一性抑制剂。IBMX抑制了磷酸二脂酶，cAMP的增加激活了PKA，其结果是减少增殖，增加分化和诱发凋亡.IBMX抑制由苯肾上腺素诱导的色胺（来自于神经内分泌上皮细胞的减少粘液IC50:1.3μM）的减少。也作为腺苷受体拮抗剂。 |
| 结构式： |
 |
 |
|
声明：以上信息未经本网证实,仅供参考,华夏化工网不承担任何风险责任. |
|
